chr2-169233504-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 3P and 3B. PM2PP2BP4_ModerateBS1_Supporting
The NM_004525.3(LRP2):c.5005A>G(p.Asn1669Asp) variant causes a missense change. The variant allele was found at a frequency of 0.000113 in 1,614,184 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. N1669N) has been classified as Likely benign.
Frequency
Consequence
NM_004525.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LRP2 | NM_004525.3 | c.5005A>G | p.Asn1669Asp | missense_variant | 30/79 | ENST00000649046.1 | |
LRP2 | XM_011511183.4 | c.5005A>G | p.Asn1669Asp | missense_variant | 30/78 | ||
LRP2 | XM_047444340.1 | c.4081A>G | p.Asn1361Asp | missense_variant | 30/79 | ||
LRP2 | XM_011511184.3 | c.2716A>G | p.Asn906Asp | missense_variant | 15/64 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LRP2 | ENST00000649046.1 | c.5005A>G | p.Asn1669Asp | missense_variant | 30/79 | NM_004525.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152180Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000171 AC: 43AN: 251448Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135892
GnomAD4 exome AF: 0.000110 AC: 161AN: 1461886Hom.: 1 Cov.: 32 AF XY: 0.0000976 AC XY: 71AN XY: 727248
GnomAD4 genome AF: 0.000138 AC: 21AN: 152298Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74472
ClinVar
Submissions by phenotype
Donnai-Barrow syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 28, 2021 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 10, 2022 | This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 1669 of the LRP2 protein (p.Asn1669Asp). This variant is present in population databases (rs143413559, gnomAD 0.08%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with LRP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 332165). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LRP2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2022 | The c.5005A>G (p.N1669D) alteration is located in exon 30 (coding exon 30) of the LRP2 gene. This alteration results from a A to G substitution at nucleotide position 5005, causing the asparagine (N) at amino acid position 1669 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Hearing loss and Retinal dystrophy Uncertain:1
Uncertain significance, no assertion criteria provided | research | National Institute on Deafness and Communication Disorders, National Institutes of Health | Feb 22, 2021 | - - |
Intellectual disability Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille | Jan 01, 2019 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at